Belgian Cancer Registry

CANCER FACT SHEET 2024
PANCREATIC CANCER
ICD-10 C25

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

ADC: Adenocarcinoma.

NENs: Neuroendocrine neoplasms.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Pancreatic cancer incidence: by region 5

1.1.1. Pancreatic cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Pancreatic cancer incidence: by tumour stage 7

1.2.1. Pancreatic cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.2. Pancreatic cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Pancreatic cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.3. Pancreatic cancer incidence: by tumour type 9

1.3.1. Pancreatic cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

1.4. Pancreatic cancer incidence: by tumour type and tumour stage 10

1.4.1. Pancreatic cancer incidence by tumour type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 10

2. CANCER INCIDENCE TRENDS 11

2.1. Pancreatic cancer incidence trends: by region 11

2.1.1. Pancreatic cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 11

2.1.2. Pancreatic cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 13

2.2. Pancreatic cancer incidence trends: by tumour stage 14

2.2.1. Pancreatic cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 14

2.3. Pancreatic cancer incidence trends: by age group 16

2.3.1. Pancreatic cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 16

2.3.2. Pancreatic cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

3. CANCER PREVALENCE 18

3.1. Pancreatic cancer prevalence: by region 18

3.1.1. Pancreatic cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 18

4. CANCER SURVIVAL 19

4.1. Pancreatic cancer survival: by region 19

4.1.1. Pancreatic cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 19

4.2. Pancreatic cancer survival: by tumour stage 21

4.2.1. Pancreatic cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 21
4.2.2. Pancreatic cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024 22
4.2.3. Pancreatic cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024 23
4.3. Pancreatic cancer survival: by tumour type and tumour stage 24
4.3.1. Pancreatic cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024 24
5. CANCER SURVIVAL TRENDS 27
5.1. Pancreatic cancer survival trends: by tumour stage 27
5.1.1. Pancreatic cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024 27
5.2. Pancreatic cancer survival trends: by tumour type and tumour stage 29
5.2.1. Pancreatic cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024 29
6. CANCER MORTALITY 33
6.1. Pancreatic cancer mortality: by region 33
6.1.1. Pancreatic cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 33
7. CANCER MORTALITY TRENDS 35
7.1. Pancreatic cancer mortality trends: by region 35
7.1.1. Pancreatic cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 35
7.1.2. Pancreatic cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 36

1.1. Pancreatic cancer incidence: by region

1.1.1. Pancreatic cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	3	2	2	2	16	22	43	97	137	210	237	199	158	85	26	3	1,242	22.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.5]	[0.5]	[0.5]	[4.2]	[5.9]	[10.9]	[24.3]	[36.1]	[64.6]	[88.2]	[93.4]	[124.9]	[103.5]	[79.8]	[47.1]	[21.4]	(21.2; 23.7)
Brussels	0	0	0	0	0	0	0	1	4	3	6	10	14	15	11	9	12	4	1	1	91	22.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[8.8]	[6.8]	[14.5]	[27.6]	[47.4]	[69.0]	[64.8]	[69.9]	[145.9]	[79.0]	[44.5]	[177.6]	[14.9]	(17.6; 27.0)
Flanders	0	0	0	0	1	0	2	1	7	9	20	56	78	119	152	128	105	51	22	1	752	21.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[0.5]	[3.1]	[4.2]	[8.9]	[23.4]	[33.6]	[59.3]	[91.5]	[94.8]	[125.3]	[91.7]	[100.6]	[23.8]	[22.3]	(20.2; 23.3)
Wallonia	0	0	0	0	2	2	0	0	5	10	17	31	45	76	74	62	41	30	3	1	399	23.7
	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[1.8]	[0.0]	[0.0]	[4.3]	[8.6]	[13.5]	[25.1]	[38.1]	[74.3]	[86.5]	[95.3]	[118.7]	[139.8]	[35.4]	[62.3]	[22.1]	(21.3; 26.0)
Females																						
Belgium	0	0	1	1	0	5	7	6	9	24	54	87	119	161	190	192	171	121	43	5	1,196	18.3
	[0.0]	[0.0]	[0.3]	[0.3]	[0.0]	[1.4]	[1.8]	[1.6]	[2.3]	[6.5]	[14.0]	[22.2]	[30.8]	[46.7]	[63.6]	[75.0]	[98.3]	[89.3]	[59.7]	[23.1]	[20.0]	(17.3; 19.3)
Brussels	0	0	0	0	0	0	1	1	0	2	2	8	4	11	8	7	11	6	1	1	63	12.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[2.1]	[0.0]	[4.8]	[5.2]	[23.3]	[13.1]	[43.7]	[37.2]	[37.8]	[85.9]	[62.2]	[17.7]	[47.6]	[9.9]	(9.3; 15.4)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	1	1	0	2	3	4	5	18	35	48	67	101	108	106	110	83	27	4	723	18.2
	[0.0]	[0.0]	[0.5]	[0.5]	[0.0]	[1.0]	[1.4]	[1.9]	[2.2]	[8.5]	[15.8]	[20.6]	[28.9]	[48.9]	[61.0]	[68.5]	[100.4]	[95.7]	[59.6]	[31.1]	[21.0]	(16.9; 19.6)
Wallonia	0	0	0	0	0	3	3	1	4	4	17	31	48	49	74	79	50	32	15	0	410	19.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.8]	[2.5]	[0.8]	[3.4]	[3.4]	[13.5]	[24.8]	[38.8]	[43.3]	[74.1]	[95.5]	[97.1]	[81.7]	[71.1]	[0.0]	[21.8]	(18.0; 21.8)

1.2. Pancreatic cancer incidence: by tumour stage

1.2.1. Pancreatic cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	47 [1.4]	122 [12.5]	103 [22.4]	272 [4.7]	4.9 (4.3; 5.5)	54 [1.6]	120 [11.7]	140 [21.2]	315 [5.3]	4.8 (4.3; 5.3)
II	22 [0.7]	86 [8.8]	66 [14.3]	174 [3.0]	3.1 (2.7; 3.6)	24 [0.7]	55 [5.3]	66 [10.0]	145 [2.4]	2.2 (1.8; 2.6)
III	17 [0.5]	59 [6.1]	37 [8.0]	113 [1.9]	2.1 (1.7; 2.4)	19 [0.6]	50 [4.9]	66 [10.0]	135 [2.3]	2.0 (1.7; 2.4)
IV	92 [2.7]	295 [30.3]	242 [52.5]	629 [10.9]	11.4 (10.5; 12.3)	86 [2.6]	224 [21.8]	236 [35.8]	546 [9.2]	8.4 (7.7; 9.1)
X/NA	9 [0.3]	22 [2.3]	23 [5.0]	54 [0.9]	1.0 (0.7; 1.2)	10 [0.3]	21 [2.0]	24 [3.6]	55 [0.9]	0.8 (0.6; 1.1)

1.2.2. Pancreatic cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	13 [0.4]	44 [4.5]	25 [5.4]	82 [1.4]	1.5 (1.2; 1.8)	34 [1.0]	48 [4.7]	21 [3.2]	103 [1.7]	1.7 (1.4; 2.0)
II	21 [0.6]	63 [6.5]	29 [6.3]	113 [1.9]	2.0 (1.6; 2.4)	23 [0.7]	47 [4.6]	27 [4.1]	98 [1.6]	1.6 (1.3; 1.9)
III	14 [0.4]	36 [3.7]	18 [3.9]	68 [1.2]	1.2 (0.9; 1.5)	16 [0.5]	32 [3.1]	12 [1.8]	60 [1.0]	1.0 (0.7; 1.2)
IV	24 [0.7]	96 [9.9]	60 [13.0]	180 [3.1]	3.2 (2.8; 3.7)	27 [0.8]	69 [6.7]	42 [6.4]	138 [2.3]	2.2 (1.8; 2.6)
X/NA	115 [3.4]	345 [35.4]	339 [73.6]	799 [13.8]	14.6 (13.6; 15.6)	93 [2.8]	274 [26.6]	430 [65.2]	797 [13.4]	11.9 (11.0; 12.7)

1.2.3. Pancreatic cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	38 [1.1]	93 [9.6]	84 [18.2]	215 [3.7]	3.9 (3.4; 4.4)	50 [1.5]	85 [8.3]	118 [17.9]	253 [4.2]	3.8 (3.4; 4.3)
II	24 [0.7]	88 [9.0]	72 [15.6]	184 [3.2]	3.3 (2.8; 3.8)	23 [0.7]	67 [6.5]	78 [11.8]	169 [2.8]	2.6 (2.2; 3.0)
III	27 [0.8]	86 [8.8]	52 [11.3]	165 [2.8]	3.0 (2.5; 3.4)	28 [0.8]	76 [7.4]	76 [11.5]	180 [3.0]	2.7 (2.3; 3.2)
IV	94 [2.8]	304 [31.2]	245 [53.2]	643 [11.1]	11.6 (10.7; 12.5)	86 [2.6]	231 [22.4]	239 [36.3]	556 [9.3]	8.6 (7.9; 9.3)
X/NA	4 [0.1]	13 [1.3]	18 [3.9]	35 [0.6]	0.6 (0.4; 0.9)	6 [0.2]	11 [1.1]	21 [3.2]	38 [0.6]	0.6 (0.4; 0.7)

1.3. Pancreatic cancer incidence: by tumour type

1.3.1. Pancreatic cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
ADC	114 [3.4]	457 [46.9]	321 [69.7]	892 [15.4]	16.1 (15.0; 17.1)	126 [3.8]	380 [36.9]	368 [55.8]	874 [14.6]	13.6 (12.7; 14.5)
NENs	63 [1.9]	85 [8.7]	46 [10.0]	194 [3.3]	3.4 (2.9; 3.9)	58 [1.7]	56 [5.4]	23 [3.5]	138 [2.3]	2.3 (1.9; 2.6)
Other and unspecified	10 [0.3]	42 [4.3]	104 [22.6]	156 [2.7]	3.0 (2.5; 3.5)	9 [0.3]	34 [3.3]	141 [21.4]	184 [3.1]	2.5 (2.1; 2.8)

1.4. Pancreatic cancer incidence: by tumour type and tumour stage

1.4.1. Pancreatic cancer incidence by tumour type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
ADC	**I**	11 [0.3]	55 [5.7]	49 [10.6]	115 [2.0]	2.1 (1.7; 2.5)	19 [0.6]	54 [5.2]	73 [11.1]	146 [2.4]	2.2 (1.9; 2.6)
	II	12 [0.4]	69 [7.1]	49 [10.6]	130 [2.2]	2.4 (1.9; 2.8)	14 [0.4]	55 [5.3]	59 [9.0]	128 [2.1]	2.0 (1.6; 2.3)
	III	20 [0.6]	76 [7.8]	37 [8.0]	133 [2.3]	2.4 (2.0; 2.8)	20 [0.6]	66 [6.4]	48 [7.3]	134 [2.2]	2.1 (1.7; 2.5)
	IV	69 [2.0]	250 [25.7]	177 [38.4]	496 [8.6]	8.9 (8.1; 9.7)	71 [2.1]	201 [19.5]	175 [26.6]	447 [7.5]	7.0 (6.4; 7.7)
	X/NA	2 [0.1]	7 [0.7]	9 [2.0]	18 [0.3]	0.3 (0.2; 0.5)	2 [0.1]	4 [0.4]	13 [2.0]	19 [0.3]	0.3 (0.1; 0.4)
NENs	**I**	23 [0.7]	36 [3.7]	20 [4.3]	79 [1.4]	1.4 (1.1; 1.7)	31 [0.9]	27 [2.6]	13 [2.0]	71 [1.2]	1.2 (0.9; 1.4)
	II	10 [0.3]	13 [1.3]	10 [2.2]	33 [0.6]	0.6 (0.4; 0.8)	8 [0.2]	6 [0.6]	4 [0.6]	19 [0.3]	0.3 (0.2; 0.5)
	III	5 [0.1]	5 [0.5]	3 [0.7]	13 [0.2]	0.2 (0.1; 0.4)	6 [0.2]	4 [0.4]	1 [0.2]	11 [0.2]	0.2 (0.1; 0.3)
	IV	23 [0.7]	26 [2.7]	12 [2.6]	61 [1.1]	1.1 (0.8; 1.3)	9 [0.3]	13 [1.3]	4 [0.6]	26 [0.4]	0.4 (0.3; 0.6)
	X/NA	2 [0.1]	5 [0.5]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)	4 [0.1]	6 [0.6]	1 [0.2]	11 [0.2]	0.2 (0.1; 0.3)
Other and unspecified	**I**	4 [0.1]	2 [0.2]	15 [3.3]	21 [0.4]	0.4 (0.2; 0.6)	0 [0.0]	4 [0.4]	32 [4.9]	36 [0.6]	0.5 (0.3; 0.6)
	II	2 [0.1]	6 [0.6]	13 [2.8]	21 [0.4]	0.4 (0.2; 0.6)	1 [0.0]	6 [0.6]	15 [2.3]	22 [0.4]	0.3 (0.2; 0.4)
	III	2 [0.1]	5 [0.5]	12 [2.6]	19 [0.3]	0.4 (0.2; 0.6)	2 [0.1]	6 [0.6]	27 [4.1]	35 [0.6]	0.5 (0.3; 0.6)
	IV	2 [0.1]	28 [2.9]	56 [12.2]	86 [1.5]	1.6 (1.3; 2.0)	6 [0.2]	17 [1.7]	60 [9.1]	83 [1.4]	1.1 (0.9; 1.4)
	X/NA	0 [0.0]	1 [0.1]	8 [1.7]	9 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	1 [0.1]	7 [1.1]	8 [0.1]	0.1 (0.0; 0.2)

2.1. Pancreatic cancer incidence trends: by region

2.1.1. Pancreatic cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	572	545	615	647	597	713	788	782	814	860	873	890	900	984	1,054	1,054	1,046	1,181	1,134	1,149	1,242		
	CR	11.2	10.7	12.0	12.5	11.4	13.5	14.8	14.6	15.0	15.8	15.9	16.2	16.3	17.7	18.8	18.7	18.5	20.8	19.9	19.9	21.4		
	ESR2013	14.1	13.0	14.8	14.9	13.8	16.2	17.8	17.3	17.7	18.5	18.4	18.4	18.6	19.8	21.1	20.5	20.2	22.4	21.3	21.0	22.5	2.6 (2.3; 3.0)	2004-2024
																							3.7 (2.8; 4.8)	2004-2012
																							1.9 (1.3; 2.5)	2013-2024
Brussels	**N**	50	39	39	62	66	63	69	62	73	63	68	84	67	83	75	77	69	86	74	84	91		
	CR	10.4	8.1	8.0	12.5	13.1	12.2	13.1	11.4	13.2	11.2	12.0	14.7	11.6	14.3	12.8	13.0	11.5	14.4	12.3	13.8	14.9		
	ESR2013	14.8	11.8	11.2	18.7	19.7	18.9	19.7	17.4	21.0	17.9	18.9	22.7	18.2	22.5	20.2	20.0	17.8	22.7	19.7	20.6	22.3	2.8 (1.6; 4.0)	2004-2024
																							9.6 (3.6; 15.9)	2004-2009
																							0.0 (-5.4; 5.7)	2010-2013
																							0.8 (-1.2; 2.9)	2014-2024
Flanders	**N**	335	325	360	354	356	397	443	430	484	497	489	513	545	568	663	623	620	683	685	698	752		
	CR	11.3	10.9	12.0	11.7	11.7	13.0	14.4	13.8	15.4	15.8	15.4	16.1	17.0	17.6	20.5	19.1	18.9	20.7	20.7	20.8	22.3		
	ESR2013	13.7	12.9	14.2	13.2	13.5	14.7	16.3	15.3	17.0	17.3	16.6	17.1	18.1	18.4	21.5	19.5	19.3	20.8	20.6	20.5	21.8	2.7 (2.3; 3.1)	2004-2024
Wallonia	**N**	187	181	216	231	175	253	276	290	257	300	316	293	288	333	316	354	357	412	375	367	399		

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR	11.4	11.0	13.0	13.9	10.4	15.0	16.2	16.9	14.9	17.3	18.1	16.7	16.4	18.9	17.9	19.9	20.0	23.1	20.9	20.4	22.1		
	ESR2013	14.7	13.7	16.9	17.4	13.2	18.6	20.3	21.2	18.3	21.1	21.8	20.0	19.4	22.2	20.5	22.4	22.6	25.5	23.2	22.2	23.7	2.5 (1.7; 3.2)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Pancreatic cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	499	531	575	546	582	663	737	758	750	814	848	893	903	900	990	1,003	1,028	1,118	1,049	1,124	1,196		
	CR	9.4	10.0	10.7	10.1	10.7	12.1	13.3	13.6	13.3	14.4	14.9	15.7	15.8	15.6	17.1	17.3	17.6	19.1	17.9	18.9	20.0		
	ESR2013	9.6	10.1	10.8	10.2	10.6	12.0	13.1	13.4	13.1	14.0	14.6	15.1	15.1	15.0	16.2	16.3	16.4	17.7	16.5	17.5	18.3	3.2 (2.9; 3.5)	2004-2024
																							4.4 (3.7; 5.0)	2004-2014
																							2.1 (1.5; 2.7)	2015-2024
Brussels	**N**	43	35	68	39	59	63	69	70	67	69	79	73	82	86	72	74	71	84	83	100	63		
	CR	8.3	6.7	12.9	7.3	10.9	11.4	12.3	12.1	11.4	11.6	13.2	12.1	13.5	14.1	11.8	12.0	11.4	13.5	13.3	15.8	9.9		
	ESR2013	9.1	7.7	15.0	8.2	12.5	13.6	14.9	13.8	13.8	13.5	16.5	14.9	16.4	17.6	14.4	14.6	14.4	16.8	16.9	19.7	12.3	2.6 (1.3; 3.9)	2004-2024
																							5.6 (2.7; 8.6)	2004-2014
																							-0.3 (-3.1; 2.5)	2015-2024
Flanders	**N**	283	311	301	319	316	381	416	416	446	463	499	493	517	508	616	566	626	675	625	660	723		
	CR	9.3	10.2	9.8	10.3	10.1	12.1	13.1	13.0	13.9	14.3	15.4	15.1	15.8	15.4	18.6	17.0	18.7	20.1	18.5	19.3	21.0		
	ESR2013	9.3	10.1	9.7	10.1	9.8	11.6	12.5	12.4	13.1	13.4	14.4	14.0	14.5	13.9	16.9	15.3	16.5	17.6	16.3	16.9	18.2	3.5 (3.1; 3.9)	2004-2024
																							4.7 (3.5; 5.8)	2004-2012
																							2.7 (2.0; 3.4)	2013-2024
Wallonia	**N**	173	185	206	188	207	219	252	272	237	282	270	327	304	306	302	363	331	359	341	364	410		
	CR	9.9	10.6	11.7	10.6	11.6	12.3	14.0	15.0	13.0	15.4	14.7	17.8	16.5	16.5	16.3	19.5	17.8	19.3	18.2	19.4	21.8		
	ESR2013	10.2	10.9	11.8	10.8	11.7	12.6	14.0	15.2	13.0	15.1	14.3	17.2	15.9	16.2	15.4	18.6	16.7	18.1	16.8	17.9	19.9	3.0 (2.5; 3.5)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Pancreatic cancer incidence trends: by tumour stage

2.2.1. Pancreatic cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
I	**N**	137	179	186	228	215			156	216	189	200	253		
	CR	2.4	3.2	3.3	4.0	3.7			2.7	3.7	3.2	3.4	4.2		
	ESR2013	2.6	3.4	3.5	4.2	3.9	9.1 (6.9; 11.4)	2004-2024	2.5	3.4	2.9	3.1	3.8	10.1 (8.9; 11.2)	2004-2024
							8.6 (6.5; 10.8)	2004-2021							
							12.1 (-3.4; 30.0)	2022-2024							
II	**N**	168	176	186	158	184			150	169	144	200	169		
	CR	3.0	3.1	3.3	2.7	3.2			2.6	2.9	2.5	3.4	2.8		
	ESR2013	3.3	3.3	3.5	2.9	3.3	1.0 (0.2; 1.8)	2004-2024	2.4	2.7	2.3	3.1	2.6	1.3 (0.2; 2.5)	2004-2024
							6.5 (4.3; 8.6)	2004-2013						7.3 (3.4; 11.5)	2004-2011
							-3.2 (-4.8; -1.6)	2014-2024						1.2 (-4.3; 7.0)	2012-2015
														-3.0 (-5.6; -0.3)	2016-2024
III	**N**	160	176	173	183	165			152	169	162	161	180		
	CR	2.8	3.1	3.0	3.2	2.8			2.6	2.9	2.8	2.7	3.0		
	ESR2013	3.1	3.3	3.2	3.3	3.0	7.9 (6.2; 9.6)	2004-2024	2.5	2.7	2.6	2.5	2.7	5.8 (4.2; 7.3)	2004-2024
							5.4 (2.2; 8.7)	2004-2015						1.8 (-0.8; 4.4)	2004-2015
							11.0 (6.8; 15.5)	2016-2024						21.3 (13.3; 30.0)	2016-2019
														3.1 (-3.8; 10.5)	2020-2024
IV	**N**	520	600	561	554	643			516	527	507	524	556		
	CR	9.2	10.6	9.8	9.6	11.1			8.8	9.0	8.6	8.8	9.3		
	ESR2013	10.0	11.3	10.5	10.1	11.6	4.5 (3.9; 5.1)	2004-2024	8.3	8.4	7.9	8.2	8.6	5.3 (4.9; 5.8)	2004-2024

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
							5.7 (4.7; 6.7)	2004-2016						6.9 (6.0; 7.8)	2004-2016
							2.8 (1.2; 4.4)	2017-2024						3.0 (1.7; 4.4)	2017-2024
X/NA	**N**	61	50	28	26	35			54	37	47	39	38		
	CR	1.1	0.9	0.5	0.5	0.6			0.9	0.6	0.8	0.7	0.6		
	ESR2013	1.2	1.0	0.6	0.5	0.6	-10.8 (-11.8; -9.8)	2004-2024	0.8	0.5	0.7	0.5	0.6	-9.3 (-10.4; -8.1)	2004-2024
							-3.5 (-5.4; -1.6)	2004-2016						-1.5 (-4.0; 0.9)	2004-2015
							-20.8 (-23.2; -18.3)	2017-2024						-17.9 (-20.4; -15.3)	2016-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Pancreatic cancer incidence trends: by age group

2.3.1. Pancreatic cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	133	140	145	169	137	161	157	176	166	166	195	180	162	183	185	202	186	219	187	203	187		
	CR	4.2	4.4	4.5	5.2	4.2	4.9	4.8	5.3	5.0	5.0	5.9	5.4	4.9	5.5	5.5	6.1	5.6	6.6	5.6	6.0	5.5		
	ESR2013	4.4	4.6	4.7	5.4	4.3	5.1	4.9	5.4	5.0	5.0	5.8	5.4	4.8	5.4	5.4	5.9	5.4	6.4	5.4	5.9	5.5	1.2 (0.7; 1.7)	2004-2024
60-74	**N**	285	250	267	287	277	331	350	351	392	413	378	417	396	462	508	522	476	563	524	527	584		
	CR	41.9	36.5	38.9	41.0	38.9	45.5	47.2	46.4	51.0	52.7	47.4	51.3	47.6	53.9	57.8	58.1	51.9	60.2	55.4	54.9	60.0		
	ESR2013	41.6	36.3	38.9	41.4	39.3	46.7	48.5	48.2	51.9	54.6	49.3	52.6	49.1	55.1	59.0	59.2	52.8	61.1	56.3	55.9	61.4	2.3 (1.9; 2.8)	2004-2024
																							3.7 (2.5; 4.9)	2004-2013
																							1.3 (0.3; 2.2)	2014-2024
75+	**N**	154	155	203	191	183	221	281	255	256	281	300	293	342	339	361	329	383	399	423	419	471		
	CR	52.5	51.2	64.6	58.6	54.3	64.0	79.4	70.6	69.4	74.7	78.2	74.8	86.6	85.9	90.9	81.4	92.6	95.9	98.1	94.1	102.3		
	ESR2013	51.1	48.4	62.6	54.8	53.4	61.4	76.7	68.3	69.0	72.3	75.7	73.2	85.0	84.3	90.6	80.0	92.2	94.7	98.1	92.6	101.6	3.5 (2.9; 4.1)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Pancreatic cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	85	102	99	97	107	117	129	142	136	154	134	158	179	149	173	158	144	172	159	179	193		
	CR	2.7	3.2	3.1	3.0	3.3	3.6	4.0	4.4	4.2	4.7	4.1	4.8	5.4	4.5	5.3	4.8	4.4	5.2	4.8	5.4	5.8		
	ESR2013	2.8	3.4	3.2	3.1	3.4	3.7	4.0	4.4	4.2	4.7	4.0	4.7	5.3	4.4	5.2	4.7	4.2	5.1	4.7	5.3	5.7	2.9 (2.3; 3.5)	2004-2024
																							4.5 (3.1; 5.9)	2004-2014
																							1.3 (-0.1; 2.7)	2015-2024
60-74	**N**	207	227	233	231	221	268	297	274	279	297	346	332	349	359	387	417	416	460	414	461	470		
	CR	26.7	29.3	30.2	29.6	28.0	33.5	36.7	33.3	33.4	35.1	40.3	38.1	39.1	39.1	41.2	43.5	42.6	46.3	41.2	45.3	45.7		
	ESR2013	26.1	28.7	29.9	29.4	28.2	33.9	36.9	34.0	34.0	35.8	41.2	39.1	39.5	39.9	41.6	43.8	42.9	46.4	41.5	45.7	46.1	2.8 (2.4; 3.2)	2004-2024
																							3.8 (2.8; 4.9)	2004-2013
																							1.9 (1.1; 2.7)	2014-2024
75+	**N**	206	202	243	218	254	277	311	342	335	363	368	401	375	392	430	427	468	485	473	483	532		
	CR	39.6	38.0	44.6	39.1	44.6	47.9	53.0	57.6	55.8	60.1	60.3	65.0	60.8	64.0	70.4	69.5	75.4	78.4	74.6	74.8	80.7		
	ESR2013	39.7	38.2	44.3	38.8	44.2	46.9	52.0	58.2	56.2	59.0	60.4	65.1	60.8	64.5	70.7	70.4	76.0	78.8	75.8	76.3	81.3	4.0 (3.6; 4.4)	2004-2024
																							5.3 (4.3; 6.3)	2004-2013
																							3.0 (2.2; 3.7)	2014-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Pancreatic cancer prevalence: by region

3.1.1. Pancreatic cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	769	1,826	2,322	2,549	2,655	755	1,739	2,223	2,471	2,578
	CR	13.2	31.3	39.8	43.7	45.5	12.6	29.0	37.1	41.2	43.0
	ESR2013	13.5	32.1	40.8	44.9	46.8	11.7	27.2	34.7	38.6	40.2
Brussels	**N**	50	121	145	157	162	36	117	153	171	180
	CR	8.1	19.7	23.6	25.5	26.3	5.6	18.3	23.9	26.7	28.1
	ESR2013	11.9	28.6	35.0	37.9	39.2	7.2	22.7	29.4	32.9	34.7
Flanders	**N**	478	1,155	1,476	1,615	1,684	462	1,070	1,360	1,513	1,572
	CR	14.1	34.0	43.4	47.5	49.5	13.3	30.9	39.3	43.7	45.4
	ESR2013	13.5	32.8	42.0	45.9	47.9	12.0	27.8	35.3	39.2	40.7
Wallonia	**N**	241	550	701	777	809	257	552	710	787	826
	CR	13.3	30.3	38.6	42.8	44.6	13.6	29.2	37.6	41.6	43.7
	ESR2013	13.6	31.2	39.8	44.2	46.2	12.4	27.1	34.9	38.7	40.6

4.1. Pancreatic cancer survival: by region

4.1.1. Pancreatic cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All ages 15+**	20,746	43.6% (42.9%; 44.3%)	20.4% (19.8%; 21.0%)	15.4% (14.8%; 16.0%)	13.0% (12.1%; 14.0%)
Males						
Belgium	**All ages 15+**	10,582	44.2% (43.2%; 45.2%)	21.1% (20.3%; 22.0%)	16.0% (15.1%; 16.9%)	13.2% (11.8%; 14.7%)
	15-59	1,889	60.0% (57.8%; 62.3%)	32.8% (30.6%; 35.0%)	27.2% (25.1%; 29.6%)	23.1% (20.5%; 25.9%)
	60-74	4,952	49.0% (47.7%; 50.5%)	23.1% (21.9%; 24.4%)	17.3% (16.1%; 18.6%)	14.6% (13.1%; 16.3%)
	75+	3,741	29.8% (28.3%; 31.4%)	12.5% (11.3%; 13.9%)	8.5% (7.2%; 10.0%)	6.1% (3.9%; 9.3%)
Brussels	**All ages 15+**	779	42.7% (39.3%; 46.5%)	16.7% (14.0%; 19.9%)	12.0% (9.5%; 15.2%)	9.5% (6.6%; 13.8%)
	15-59	190	50.1% (43.5%; 57.8%)	19.1% (13.9%; 26.2%)	14.7% (10.0%; 21.8%)	13.4% (8.5%; 21.0%)
	60-74	357	47.4% (42.4%; 52.9%)	21.7% (17.5%; 26.9%)	15.5% (11.6%; 20.7%)	12.6% (8.1%; 19.5%)
	75+	232	29.3% (23.7%; 36.3%)	7.2% (4.2%; 12.3%)	5.0% (2.4%; 10.5%)	FU<10y
Flanders	**All ages 15+**	6,324	45.3% (44.1%; 46.6%)	22.4% (21.3%; 23.6%)	17.1% (16.0%; 18.3%)	14.5% (12.8%; 16.5%)
	15-59	1,043	62.5% (59.6%; 65.5%)	36.2% (33.3%; 39.4%)	30.3% (27.4%; 33.5%)	26.1% (22.8%; 29.9%)
	60-74	2,884	50.9% (49.1%; 52.8%)	24.4% (22.7%; 26.1%)	18.5% (16.9%; 20.3%)	15.6% (13.6%; 17.8%)
	75+	2,397	31.1% (29.2%; 33.1%)	14.0% (12.4%; 15.7%)	9.7% (8.1%; 11.6%)	7.9% (5.1%; 12.3%)
Wallonia	**All ages 15+**	3,479	42.5% (40.8%; 44.2%)	19.7% (18.3%; 21.2%)	14.7% (13.3%; 16.3%)	11.4% (9.2%; 14.1%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-59	656	58.8% (55.2%; 62.7%)	31.0% (27.5%; 34.9%)	25.8% (22.4%; 29.8%)	21.3% (17.2%; 26.4%)
	60-74	1,711	46.2% (43.9%; 48.7%)	21.4% (19.4%; 23.6%)	15.6% (13.6%; 17.8%)	13.4% (10.9%; 16.5%)
	75+	1,112	27.1% (24.5%; 30.0%)	10.6% (8.6%; 13.0%)	6.8% (4.8%; 9.6%)	4.0% (1.7%; 9.3%)
Females						
Belgium	**All ages 15+**	10,164	42.9% (41.9%; 43.9%)	19.6% (18.8%; 20.5%)	14.8% (14.0%; 15.7%)	12.8% (11.5%; 14.1%)
	15-59	1,650	68.7% (66.5%; 71.0%)	39.6% (37.2%; 42.1%)	33.2% (30.8%; 35.8%)	28.4% (25.7%; 31.4%)
	60-74	4,053	49.7% (48.2%; 51.3%)	21.5% (20.2%; 22.9%)	15.4% (14.1%; 16.7%)	11.7% (10.2%; 13.4%)
	75+	4,461	27.2% (25.9%; 28.6%)	10.5% (9.5%; 11.5%)	7.5% (6.5%; 8.7%)	7.9% (5.7%; 11.0%)
Brussels	**All ages 15+**	783	41.5% (38.1%; 45.2%)	17.8% (15.1%; 20.9%)	14.9% (12.4%; 18.0%)	12.9% (10.1%; 16.6%)
	15-59	163	69.8% (63.1%; 77.3%)	41.1% (34.0%; 49.6%)	37.7% (30.7%; 46.4%)	36.7% (29.3%; 45.9%)
	60-74	284	46.7% (41.2%; 53.0%)	19.4% (15.1%; 24.8%)	13.8% (9.9%; 19.1%)	11.8% (7.6%; 18.1%)
	75+	336	23.5% (19.2%; 28.7%)	4.7% (2.7%; 8.2%)	4.3% (2.3%; 8.1%)	FU<10y
Flanders	**All ages 15+**	5,988	44.2% (42.9%; 45.5%)	20.6% (19.5%; 21.8%)	15.5% (14.5%; 16.7%)	13.8% (12.3%; 15.6%)
	15-59	890	70.3% (67.4%; 73.4%)	40.3% (37.0%; 43.8%)	33.0% (29.8%; 36.5%)	28.7% (25.2%; 32.7%)
	60-74	2,353	51.8% (49.8%; 53.9%)	23.5% (21.8%; 25.4%)	16.8% (15.2%; 18.7%)	12.1% (10.1%; 14.5%)
	75+	2,745	29.2% (27.5%; 31.0%)	11.8% (10.5%; 13.2%)	8.7% (7.4%; 10.3%)	10.6% (7.6%; 14.7%)
Wallonia	**All ages 15+**	3,393	41.0% (39.4%; 42.8%)	18.2% (16.9%; 19.7%)	13.6% (12.2%; 15.0%)	10.8% (8.8%; 13.3%)
	15-59	597	66.0% (62.3%; 69.9%)	38.1% (34.2%; 42.4%)	32.3% (28.4%; 36.7%)	26.0% (21.6%; 31.3%)
	60-74	1,416	46.8% (44.3%; 49.5%)	18.6% (16.6%; 20.9%)	13.2% (11.3%; 15.5%)	10.9% (8.8%; 13.6%)
	75+	1,380	24.3% (22.0%; 26.8%)	9.2% (7.6%; 11.1%)	5.7% (4.2%; 7.8%)	3.4% (1.3%; 9.3%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2. Pancreatic cancer survival: by tumour stage

4.2.1. Pancreatic cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
cStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	20,746	43.6% (42.9%; 44.3%)	27.0% (26.3%; 27.6%)	20.4% (19.8%; 21.0%)	17.3% (16.7%; 17.9%)	15.4% (14.8%; 16.0%)	13.0% (12.1%; 14.0%)
Males							
All	10,582	44.2% (43.2%; 45.2%)	27.4% (26.5%; 28.3%)	21.1% (20.3%; 22.0%)	17.9% (17.0%; 18.8%)	16.0% (15.1%; 16.9%)	13.2% (11.8%; 14.7%)
I	1,821	74.5% (72.3%; 76.6%)	57.9% (55.4%; 60.4%)	49.6% (47.0%; 52.3%)	43.7% (40.8%; 46.8%)	40.3% (37.3%; 43.6%)	40.2% (35.5%; 45.5%)
II	1,438	62.7% (60.1%; 65.3%)	42.2% (39.6%; 45.0%)	32.6% (30.0%; 35.4%)	27.5% (24.9%; 30.3%)	22.9% (20.3%; 25.9%)	17.8% (14.3%; 22.2%)
III	969	52.6% (49.5%; 56.0%)	26.0% (23.3%; 29.1%)	16.9% (14.5%; 19.7%)	12.7% (10.4%; 15.4%)	11.9% (9.7%; 14.8%)	FU<10y
IV	4,988	24.2% (23.0%; 25.4%)	9.5% (8.7%; 10.4%)	5.3% (4.6%; 6.0%)	3.8% (3.2%; 4.4%)	3.1% (2.6%; 3.8%)	1.8% (1.2%; 2.6%)
X/NA	1,380	51.7% (49.0%; 54.5%)	37.4% (34.8%; 40.2%)	31.2% (28.6%; 34.0%)	27.7% (25.1%; 30.5%)	25.0% (22.4%; 27.9%)	20.1% (16.5%; 24.4%)
Females							
All	10,164	42.9% (41.9%; 43.9%)	26.5% (25.6%; 27.4%)	19.6% (18.8%; 20.5%)	16.6% (15.8%; 17.5%)	14.8% (14.0%; 15.7%)	12.8% (11.5%; 14.1%)
I	1,906	70.6% (68.4%; 72.7%)	53.2% (50.9%; 55.7%)	45.0% (42.5%; 47.6%)	40.5% (37.9%; 43.2%)	37.4% (34.7%; 40.3%)	35.1% (31.1%; 39.6%)
II	1,308	56.3% (53.6%; 59.1%)	35.8% (33.2%; 38.6%)	26.6% (24.1%; 29.3%)	21.8% (19.3%; 24.5%)	19.0% (16.4%; 22.0%)	16.7% (13.3%; 21.0%)
III	977	47.2% (44.1%; 50.5%)	23.7% (21.1%; 26.6%)	13.5% (11.4%; 16.0%)	9.8% (7.9%; 12.1%)	7.3% (5.5%; 9.7%)	5.5% (3.6%; 8.5%)
IV	4,600	24.0% (22.8%; 25.3%)	10.0% (9.1%; 10.9%)	4.8% (4.2%; 5.5%)	3.3% (2.8%; 4.0%)	2.4% (1.9%; 3.0%)	1.0% (0.6%; 1.7%)
X/NA	1,382	52.2% (49.6%; 55.0%)	38.0% (35.4%; 40.7%)	31.8% (29.3%; 34.6%)	28.2% (25.7%; 31.0%)	26.5% (24.0%; 29.3%)	23.3% (19.6%; 27.6%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.2. Pancreatic cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
pStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	20,746	43.6% (42.9%; 44.3%)	27.0% (26.3%; 27.6%)	20.4% (19.8%; 21.0%)	17.3% (16.7%; 17.9%)	15.4% (14.8%; 16.0%)	13.0% (12.1%; 14.0%)
Males							
All	10,582	44.2% (43.2%; 45.2%)	27.4% (26.5%; 28.3%)	21.1% (20.3%; 22.0%)	17.9% (17.0%; 18.8%)	16.0% (15.1%; 16.9%)	13.2% (11.8%; 14.7%)
I	730	90.1% (87.7%; 92.6%)	79.9% (76.7%; 83.3%)	74.0% (70.3%; 77.9%)	69.6% (65.5%; 73.9%)	65.7% (61.1%; 70.5%)	56.1% (43.8%; 71.8%)
II	1,203	79.4% (77.0%; 81.9%)	60.5% (57.6%; 63.5%)	45.4% (42.4%; 48.7%)	37.6% (34.6%; 41.0%)	32.4% (29.3%; 35.8%)	25.0% (21.2%; 29.6%)
III	640	76.6% (73.3%; 80.2%)	50.6% (46.7%; 54.9%)	39.9% (36.0%; 44.3%)	31.8% (27.8%; 36.4%)	26.7% (22.7%; 31.4%)	20.1% (14.5%; 27.9%)
IV	1,354	30.4% (28.0%; 33.0%)	13.5% (11.8%; 15.6%)	8.4% (6.9%; 10.1%)	6.2% (4.9%; 7.9%)	5.5% (4.2%; 7.1%)	3.6% (2.3%; 5.7%)
X/NA	6,671	32.5% (31.4%; 33.7%)	16.2% (15.3%; 17.2%)	11.6% (10.8%; 12.5%)	9.5% (8.7%; 10.5%)	8.6% (7.7%; 9.5%)	7.3% (6.2%; 8.7%)
Females							
All	10,164	42.9% (41.9%; 43.9%)	26.5% (25.6%; 27.4%)	19.6% (18.8%; 20.5%)	16.6% (15.8%; 17.5%)	14.8% (14.0%; 15.7%)	12.8% (11.5%; 14.1%)
I	802	91.9% (89.9%; 94.0%)	82.8% (80.0%; 85.8%)	73.7% (70.4%; 77.3%)	69.2% (65.4%; 73.1%)	65.5% (61.4%; 69.8%)	63.1% (56.1%; 71.0%)
II	1,025	80.4% (77.9%; 83.0%)	56.3% (53.2%; 59.6%)	44.3% (41.1%; 47.7%)	36.5% (33.3%; 40.0%)	32.2% (29.0%; 35.7%)	24.2% (19.7%; 29.7%)
III	479	76.4% (72.5%; 80.4%)	50.3% (45.8%; 55.2%)	33.6% (29.3%; 38.6%)	26.5% (22.3%; 31.5%)	21.4% (17.2%; 26.6%)	12.8% (7.8%; 21.1%)
IV	1,171	31.6% (29.0%; 34.4%)	15.4% (13.4%; 17.7%)	8.6% (7.0%; 10.5%)	6.3% (5.0%; 8.1%)	4.4% (3.2%; 6.0%)	1.9% (0.9%; 4.0%)
X/NA	6,695	30.9% (29.8%; 32.1%)	15.4% (14.5%; 16.4%)	10.3% (9.5%; 11.1%)	8.4% (7.6%; 9.2%)	7.4% (6.6%; 8.3%)	6.9% (5.7%; 8.3%)

4.2.3. Pancreatic cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
Stage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	20,746	43.6% (42.9%; 44.3%)	27.0% (26.3%; 27.6%)	20.4% (19.8%; 21.0%)	17.3% (16.7%; 17.9%)	15.4% (14.8%; 16.0%)	13.0% (12.1%; 14.0%)
Males							
All	10,582	44.2% (43.2%; 45.2%)	27.4% (26.5%; 28.3%)	21.1% (20.3%; 22.0%)	17.9% (17.0%; 18.8%)	16.0% (15.1%; 16.9%)	13.2% (11.8%; 14.7%)
I	1,460	75.4% (73.1%; 77.9%)	63.3% (60.6%; 66.1%)	59.0% (56.1%; 62.1%)	55.1% (51.8%; 58.6%)	51.9% (48.4%; 55.7%)	46.9% (38.7%; 56.8%)
II	1,799	66.4% (64.2%; 68.8%)	46.1% (43.7%; 48.7%)	34.0% (31.7%; 36.6%)	28.1% (25.8%; 30.6%)	24.0% (21.7%; 26.6%)	18.4% (15.6%; 21.6%)
III	1,392	60.1% (57.5%; 62.8%)	33.4% (30.9%; 36.1%)	23.6% (21.3%; 26.2%)	17.8% (15.6%; 20.4%)	15.4% (13.2%; 18.0%)	FU<10y
IV	5,154	24.6% (23.5%; 25.9%)	9.7% (8.9%; 10.6%)	5.4% (4.8%; 6.2%)	3.8% (3.3%; 4.5%)	3.2% (2.7%; 3.9%)	1.9% (1.4%; 2.7%)
X/NA	792	35.7% (32.4%; 39.3%)	23.2% (20.3%; 26.7%)	19.2% (16.4%; 22.5%)	17.4% (14.6%; 20.8%)	15.7% (12.7%; 19.3%)	14.1% (10.5%; 19.0%)
Females							
All	10,164	42.9% (41.9%; 43.9%)	26.5% (25.6%; 27.4%)	19.6% (18.8%; 20.5%)	16.6% (15.8%; 17.5%)	14.8% (14.0%; 15.7%)	12.8% (11.5%; 14.1%)
I	1,576	72.2% (69.8%; 74.5%)	59.9% (57.4%; 62.6%)	53.2% (50.5%; 56.1%)	50.3% (47.4%; 53.4%)	48.4% (45.4%; 51.6%)	48.6% (43.8%; 54.0%)
II	1,708	62.4% (60.0%; 64.8%)	40.4% (38.0%; 42.9%)	30.9% (28.6%; 33.4%)	25.8% (23.5%; 28.3%)	22.4% (20.1%; 24.9%)	17.5% (14.3%; 21.3%)
III	1,298	54.1% (51.4%; 57.0%)	29.3% (26.9%; 32.0%)	18.0% (15.8%; 20.4%)	13.1% (11.2%; 15.4%)	10.1% (8.2%; 12.4%)	6.8% (4.6%; 10.1%)
IV	4,763	24.5% (23.3%; 25.8%)	10.3% (9.5%; 11.3%)	5.1% (4.5%; 5.8%)	3.4% (2.9%; 4.1%)	2.4% (1.9%; 3.0%)	1.0% (0.6%; 1.6%)
X/NA	830	35.7% (32.5%; 39.2%)	23.1% (20.3%; 26.4%)	19.2% (16.5%; 22.3%)	16.2% (13.6%; 19.4%)	15.7% (13.0%; 19.0%)	14.4% (10.2%; 20.3%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.3. Pancreatic cancer survival: by tumour type and tumour stage

4.3.1. Pancreatic cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	Total	20,746	43.6% (42.9%; 44.3%)	27.0% (26.3%; 27.6%)	20.4% (19.8%; 21.0%)	17.3% (16.7%; 17.9%)	15.4% (14.8%; 16.0%)	13.0% (12.1%; 14.0%)
Males								
Total	All	10,582	44.2% (43.2%; 45.2%)	27.4% (26.5%; 28.3%)	21.1% (20.3%; 22.0%)	17.9% (17.0%; 18.8%)	16.0% (15.1%; 16.9%)	13.2% (11.8%; 14.7%)
	I	1,460	75.4% (73.1%; 77.9%)	63.3% (60.6%; 66.1%)	59.0% (56.1%; 62.1%)	55.1% (51.8%; 58.6%)	51.9% (48.4%; 55.7%)	46.9% (38.7%; 56.8%)
	II	1,799	66.4% (64.2%; 68.8%)	46.1% (43.7%; 48.7%)	34.0% (31.7%; 36.6%)	28.1% (25.8%; 30.6%)	24.0% (21.7%; 26.6%)	18.4% (15.6%; 21.6%)
	III	1,392	60.1% (57.5%; 62.8%)	33.4% (30.9%; 36.1%)	23.6% (21.3%; 26.2%)	17.8% (15.6%; 20.4%)	15.4% (13.2%; 18.0%)	FU<10y
	IV	5,154	24.6% (23.5%; 25.9%)	9.7% (8.9%; 10.6%)	5.4% (4.8%; 6.2%)	3.8% (3.3%; 4.5%)	3.2% (2.7%; 3.9%)	1.9% (1.4%; 2.7%)
	X/NA	792	35.7% (32.4%; 39.3%)	23.2% (20.3%; 26.7%)	19.2% (16.4%; 22.5%)	17.4% (14.6%; 20.8%)	15.7% (12.7%; 19.3%)	14.1% (10.5%; 19.0%)
ADC	All	7,970	41.7% (40.6%; 42.9%)	21.6% (20.7%; 22.6%)	14.4% (13.6%; 15.3%)	10.7% (9.9%; 11.5%)	8.5% (7.8%; 9.3%)	5.5% (4.4%; 6.9%)
	I	791	68.6% (65.2%; 72.1%)	49.3% (45.7%; 53.3%)	42.3% (38.6%; 46.5%)	37.2% (33.3%; 41.5%)	30.5% (26.5%; 35.2%)	18.7% (8.5%; 41.0%)
	II	1,451	65.8% (63.3%; 68.4%)	42.0% (39.4%; 44.8%)	28.4% (26.0%; 31.1%)	22.0% (19.7%; 24.6%)	17.8% (15.6%; 20.3%)	11.1% (8.7%; 14.2%)
	III	1,110	62.3% (59.4%; 65.3%)	31.0% (28.2%; 34.0%)	19.1% (16.7%; 21.9%)	12.0% (9.9%; 14.5%)	9.3% (7.4%; 11.8%)	FU<10y
	IV	4,113	24.3% (23.0%; 25.7%)	7.8% (7.0%; 8.7%)	3.6% (3.0%; 4.3%)	1.9% (1.4%; 2.4%)	1.3% (0.9%; 1.8%)	0.5% (0.2%; 1.0%)
	X/NA	505	27.0% (23.3%; 31.3%)	11.5% (8.9%; 14.8%)	7.3% (5.3%; 10.2%)	4.6% (2.9%; 7.4%)	3.7% (2.2%; 6.3%)	2.5% (1.1%; 5.7%)
NENs	All	1,221	85.4% (83.2%; 87.5%)	79.9% (77.4%; 82.5%)	75.9% (73.1%; 78.9%)	74.2% (71.0%; 77.5%)	73.4% (69.9%; 77.0%)	67.9% (60.9%; 75.7%)
	I	458	96.9% (94.8%; 99.0%)	96.3% (93.7%; 99.0%)	97.3% (94.4%; 100.4%)	97.1% (93.3%; 101.1%)	98.0% (93.6%; 102.6%)	96.3% (82.2%; 113.0%)
	II	204	94.3% (90.6%; 98.2%)	91.4% (86.5%; 96.5%)	87.0% (80.8%; 93.6%)	84.1% (77.1%; 91.8%)	83.6% (75.7%; 92.4%)	82.8% (70.2%; 97.6%)
	III	120	91.8% (86.5%; 97.5%)	86.5% (79.6%; 94.1%)	84.0% (76.2%; 92.5%)	85.2% (76.3%; 95.3%)	81.5% (70.9%; 93.7%)	FU<10y
	IV	341	63.4% (58.3%; 68.9%)	48.8% (43.5%; 54.7%)	38.0% (32.7%; 44.2%)	34.5% (29.1%; 40.9%)	31.9% (26.4%; 38.5%)	21.9% (15.5%; 30.9%)
	X/NA	98	80.7% (72.8%; 89.4%)	78.5% (69.9%; 88.1%)	72.7% (62.9%; 84.1%)	70.0% (59.2%; 82.7%)	70.1% (58.4%; 84.2%)	63.0% (46.8%; 84.8%)

Net Survival Probability, 2015-2024								
type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Other and unspecified	All	1,411	22.6% (20.5%; 25.0%)	15.0% (13.1%; 17.2%)	12.4% (10.6%; 14.6%)	11.0% (9.0%; 13.4%)	9.7% (7.6%; 12.3%)	10.2% (6.9%; 15.0%)
	I	216	54.3% (47.6%; 62.0%)	44.5% (37.6%; 52.7%)	39.8% (32.7%; 48.5%)	33.8% (25.4%; 44.9%)	34.4% (25.6%; 46.2%)	30.1% (15.4%; 58.9%)
	II	144	33.0% (26.0%; 42.1%)	24.1% (17.6%; 32.9%)	17.4% (11.6%; 26.0%)	12.9% (7.6%; 21.8%)	7.8% (3.5%; 17.2%)	9.3% (4.2%; 20.7%)
	III	162	21.5% (15.8%; 29.3%)	10.6% (6.6%; 17.1%)	8.9% (5.1%; 15.4%)	5.1% (2.0%; 13.0%)	5.1% (2.0%; 13.0%)	FU<10y
	IV	700	7.5% (5.8%; 9.8%)	2.0% (1.1%; 3.4%)	0.7% (0.3%; 1.8%)	0.7% (0.3%; 1.8%)	0.7% (0.3%; 1.8%)	FU<10y
	X/NA	189	35.0% (28.6%; 42.9%)	25.7% (19.6%; 33.9%)	22.8% (16.8%; 31.1%)	22.9% (16.6%; 31.6%)	18.9% (12.3%; 29.1%)	20.9% (11.4%; 38.4%)
Females								
Total	All	10,164	42.9% (41.9%; 43.9%)	26.5% (25.6%; 27.4%)	19.6% (18.8%; 20.5%)	16.6% (15.8%; 17.5%)	14.8% (14.0%; 15.7%)	12.8% (11.5%; 14.1%)
	I	1,576	72.2% (69.8%; 74.5%)	59.9% (57.4%; 62.6%)	53.2% (50.5%; 56.1%)	50.3% (47.4%; 53.4%)	48.4% (45.4%; 51.6%)	48.6% (43.8%; 54.0%)
	II	1,708	62.4% (60.0%; 64.8%)	40.4% (38.0%; 42.9%)	30.9% (28.6%; 33.4%)	25.8% (23.5%; 28.3%)	22.4% (20.1%; 24.9%)	17.5% (14.3%; 21.3%)
	III	1,298	54.1% (51.4%; 57.0%)	29.3% (26.9%; 32.0%)	18.0% (15.8%; 20.4%)	13.1% (11.2%; 15.4%)	10.1% (8.2%; 12.4%)	6.8% (4.6%; 10.1%)
	IV	4,763	24.5% (23.3%; 25.8%)	10.3% (9.5%; 11.3%)	5.1% (4.5%; 5.8%)	3.4% (2.9%; 4.1%)	2.4% (1.9%; 3.0%)	1.0% (0.6%; 1.6%)
	X/NA	830	35.7% (32.5%; 39.2%)	23.1% (20.3%; 26.4%)	19.2% (16.5%; 22.3%)	16.2% (13.6%; 19.4%)	15.7% (13.0%; 19.0%)	14.4% (10.2%; 20.3%)
ADC	All	7,587	42.5% (41.3%; 43.6%)	22.5% (21.6%; 23.5%)	14.3% (13.4%; 15.1%)	10.7% (9.9%; 11.5%)	8.9% (8.2%; 9.7%)	6.2% (5.2%; 7.3%)
	I	905	69.8% (66.7%; 73.0%)	51.8% (48.4%; 55.4%)	41.8% (38.3%; 45.5%)	36.5% (33.0%; 40.4%)	33.5% (29.9%; 37.5%)	26.4% (21.6%; 32.3%)
	II	1,369	63.2% (60.7%; 65.9%)	38.1% (35.5%; 40.9%)	27.0% (24.6%; 29.7%)	20.9% (18.6%; 23.5%)	17.9% (15.6%; 20.4%)	12.8% (9.9%; 16.5%)
	III	1,068	57.6% (54.6%; 60.7%)	29.1% (26.4%; 32.1%)	16.4% (14.2%; 19.0%)	11.0% (9.1%; 13.5%)	7.7% (5.9%; 10.0%)	4.4% (2.7%; 7.1%)
	IV	3,751	25.9% (24.5%; 27.4%)	9.4% (8.5%; 10.5%)	3.6% (3.0%; 4.3%)	1.7% (1.3%; 2.3%)	0.9% (0.6%; 1.3%)	0.3% (0.1%; 0.6%)
	X/NA	494	27.9% (24.1%; 32.2%)	11.4% (8.9%; 14.7%)	5.6% (3.9%; 8.2%)	3.4% (2.1%; 5.6%)	3.0% (1.7%; 5.3%)	1.4% (0.6%; 3.4%)
NENs	All	941	88.5% (86.3%; 90.7%)	84.3% (81.8%; 86.9%)	80.8% (77.9%; 83.8%)	79.2% (76.1%; 82.5%)	76.2% (72.6%; 79.9%)	75.1% (66.9%; 84.3%)
	I	408	97.0% (95.1%; 99.0%)	96.1% (93.6%; 98.6%)	94.1% (91.0%; 97.4%)	95.1% (91.6%; 98.6%)	94.1% (89.9%; 98.4%)	107.8% (97.8%; 118.9%)
	II	151	93.9% (89.8%; 98.2%)	91.2% (86.0%; 96.7%)	87.8% (81.6%; 94.5%)	84.9% (77.8%; 92.6%)	81.3% (73.1%; 90.4%)	77.7% (67.0%; 90.1%)
	III	56	92.2% (84.9%; 100.0%)	89.5% (81.1%; 98.8%)	89.2% (80.1%; 99.4%)	88.5% (78.4%; 99.9%)	85.7% (73.0%; 100.5%)	70.5% (43.3%; 114.7%)
	IV	223	66.3% (60.3%; 73.0%)	53.7% (47.3%; 60.9%)	45.9% (39.4%; 53.5%)	42.6% (36.0%; 50.4%)	34.4% (27.8%; 42.6%)	15.3% (8.3%; 28.0%)

Net Survival Probability, 2015-2024								
type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	103	91.7% (86.0%; 97.7%)	90.9% (84.5%; 97.9%)	89.5% (81.9%; 97.8%)	84.9% (75.7%; 95.1%)	85.7% (75.8%; 96.8%)	82.2% (56.7%; 119.3%)
Other and unspecified	All	1,649	19.2% (17.3%; 21.3%)	12.0% (10.4%; 13.8%)	9.8% (8.3%; 11.6%)	8.9% (7.3%; 10.8%)	7.7% (6.1%; 9.9%)	8.1% (5.9%; 11.2%)
	I	265	42.2% (36.3%; 49.0%)	32.3% (26.6%; 39.2%)	29.5% (23.7%; 36.6%)	29.0% (22.7%; 37.0%)	30.3% (23.5%; 38.9%)	30.2% (20.2%; 45.0%)
	II	188	30.6% (24.5%; 38.3%)	16.5% (11.6%; 23.4%)	13.6% (9.0%; 20.5%)	14.9% (9.6%; 23.0%)	9.3% (4.4%; 19.9%)	FU<10y
	III	174	20.4% (15.1%; 27.6%)	11.1% (7.1%; 17.1%)	5.0% (2.5%; 10.0%)	2.3% (0.7%; 7.0%)	1.1% (0.2%; 5.8%)	FU<10y
	IV	789	6.0% (4.6%; 8.0%)	2.3% (1.4%; 3.7%)	0.6% (0.3%; 1.6%)	0.3% (0.1%; 1.1%)	0.2% (0.0%; 0.8%)	FU<10y
	X/NA	233	27.4% (22.0%; 34.1%)	18.3% (13.6%; 24.6%)	17.7% (13.0%; 24.3%)	14.3% (9.5%; 21.4%)	12.1% (7.6%; 19.5%)	13.3% (7.9%; 22.5%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Pancreatic cancer survival trends: by tumour stage

5.1.1. Pancreatic cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	3,650	33.9% (32.4%; 35.5%)	13.2% (12.1%; 14.4%)	9.7% (8.7%; 10.8%)	3,365	34.6% (33.0%; 36.3%)	12.1% (11.0%; 13.3%)	8.8% (7.9%; 9.9%)
	I	235	64.7% (58.6%; 71.4%)	40.9% (34.5%; 48.4%)	32.9% (26.8%; 40.4%)	226	69.1% (63.0%; 75.7%)	42.9% (36.6%; 50.3%)	33.6% (27.6%; 41.0%)
	II	757	58.6% (55.1%; 62.4%)	23.6% (20.7%; 27.1%)	15.8% (13.2%; 18.9%)	711	56.9% (53.3%; 60.8%)	18.0% (15.3%; 21.1%)	12.2% (9.9%; 15.1%)
	III	257	36.4% (30.8%; 42.9%)	7.2% (4.5%; 11.3%)	3.1% (1.5%; 6.3%)	292	34.2% (29.1%; 40.2%)	5.4% (3.3%; 8.7%)	2.2% (1.0%; 4.7%)
	IV	1,373	19.0% (17.0%; 21.3%)	4.0% (3.1%; 5.2%)	2.6% (1.8%; 3.7%)	1,166	20.2% (18.0%; 22.7%)	3.8% (2.8%; 5.1%)	2.3% (1.6%; 3.4%)
	X/NA	1,029	28.0% (25.3%; 31.0%)	12.9% (10.8%; 15.3%)	10.8% (8.9%; 13.2%)	970	27.8% (25.0%; 30.8%)	12.5% (10.5%; 14.9%)	10.4% (8.5%; 12.7%)
2010-2014	All	4,090	36.3% (34.8%; 37.8%)	14.3% (13.2%; 15.5%)	11.0% (10.0%; 12.1%)	3,885	36.9% (35.4%; 38.5%)	15.1% (13.9%; 16.3%)	11.2% (10.2%; 12.3%)
	I	345	69.6% (64.6%; 75.0%)	48.9% (43.4%; 55.2%)	45.3% (39.5%; 52.1%)	376	67.6% (62.8%; 72.7%)	49.9% (44.7%; 55.7%)	45.9% (40.6%; 51.9%)
	II	920	59.8% (56.6%; 63.2%)	24.6% (21.8%; 27.7%)	17.3% (14.8%; 20.2%)	845	58.9% (55.6%; 62.4%)	25.1% (22.2%; 28.4%)	15.8% (13.3%; 18.6%)
	III	305	35.4% (30.3%; 41.3%)	5.7% (3.6%; 9.1%)	3.4% (1.8%; 6.3%)	313	41.4% (36.2%; 47.3%)	6.4% (4.1%; 9.8%)	3.8% (2.1%; 6.7%)
	IV	1,707	21.2% (19.3%; 23.2%)	4.6% (3.7%; 5.8%)	2.2% (1.6%; 3.1%)	1,518	21.9% (19.9%; 24.1%)	4.7% (3.7%; 6.0%)	2.7% (1.9%; 3.7%)
	X/NA	814	27.6% (24.7%; 31.0%)	11.4% (9.3%; 14.0%)	10.7% (8.5%; 13.3%)	836	26.5% (23.5%; 29.7%)	11.3% (9.2%; 13.8%)	9.2% (7.3%; 11.6%)
2015-2019	All	4,860	41.1% (39.7%; 42.5%)	19.1% (18.0%; 20.3%)	14.2% (13.1%; 15.4%)	4,674	40.9% (39.5%; 42.4%)	17.9% (16.8%; 19.1%)	13.6% (12.6%; 14.7%)
	I	522	74.9% (71.0%; 79.0%)	58.9% (54.3%; 63.9%)	51.7% (46.7%; 57.3%)	566	70.9% (67.0%; 74.9%)	53.0% (48.7%; 57.7%)	47.8% (43.3%; 52.8%)
	II	928	66.3% (63.2%; 69.6%)	32.6% (29.5%; 36.0%)	22.0% (19.2%; 25.2%)	879	62.0% (58.7%; 65.4%)	28.9% (25.9%; 32.2%)	21.3% (18.6%; 24.4%)

Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability		
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	536	54.2% (49.9%; 58.7%)	19.6% (16.3%; 23.4%)	12.9% (10.2%; 16.4%)	477	54.4% (50.0%; 59.2%)	16.7% (13.6%; 20.6%)	9.2% (6.7%; 12.5%)
	IV	2,285	21.8% (20.1%; 23.6%)	4.8% (4.0%; 5.8%)	2.8% (2.1%; 3.6%)	2,135	23.2% (21.4%; 25.0%)	4.9% (4.1%; 6.0%)	2.4% (1.8%; 3.2%)
	X/NA	596	34.0% (30.3%; 38.2%)	17.9% (14.8%; 21.5%)	14.2% (11.1%; 18.2%)	621	34.5% (30.8%; 38.6%)	16.2% (13.4%; 19.6%)	13.2% (10.5%; 16.6%)
2020-2024	All	5,722	46.9% (45.5%; 48.2%)	22.8% (21.6%; 24.1%)	17.9% (16.5%; 19.4%)	5,491	44.6% (43.3%; 46.0%)	21.1% (19.9%; 22.3%)	15.9% (14.6%; 17.3%)
	I	938	75.7% (72.8%; 78.7%)	59.1% (55.5%; 63.0%)	52.1% (47.0%; 57.7%)	1,010	72.9% (70.0%; 75.8%)	53.5% (50.0%; 57.2%)	49.2% (45.1%; 53.6%)
	II	871	66.5% (63.3%; 69.9%)	35.6% (32.1%; 39.6%)	27.7% (23.9%; 32.2%)	829	62.8% (59.5%; 66.4%)	33.4% (29.9%; 37.2%)	23.1% (18.9%; 28.2%)
	III	856	63.8% (60.5%; 67.3%)	26.6% (23.5%; 30.2%)	17.0% (13.7%; 21.0%)	821	53.9% (50.5%; 57.5%)	18.9% (16.2%; 22.2%)	10.8% (8.1%; 14.3%)
	IV	2,869	26.9% (25.3%; 28.6%)	5.9% (4.9%; 6.9%)	3.6% (2.7%; 4.8%)	2,628	25.6% (24.0%; 27.3%)	5.1% (4.2%; 6.1%)	2.2% (1.5%; 3.2%)
	X/NA	196	40.8% (34.2%; 48.7%)	23.0% (16.9%; 31.3%)	21.2% (14.8%; 30.3%)	209	39.3% (33.0%; 46.8%)	29.1% (22.9%; 37.0%)	24.3% (17.6%; 33.7%)

5.2. Pancreatic cancer survival trends: by tumour type and tumour stage

5.2.1. Pancreatic cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024

			Males				Females			
				Net Survival Probability				Net Survival Probability		
type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
ADC	**2004-2009**	All	2,855	32.9% (31.2%; 34.7%)	9.8% (8.7%; 11.0%)	6.3% (5.4%; 7.3%)	2,550	35.1% (33.3%; 37.1%)	8.7% (7.6%; 9.9%)	5.3% (4.4%; 6.3%)
		I	165	64.1% (56.9%; 72.3%)	35.2% (28.1%; 44.2%)	24.8% (18.4%; 33.3%)	145	70.9% (63.6%; 79.1%)	36.8% (29.4%; 46.0%)	23.5% (17.2%; 32.2%)
		II	677	59.7% (56.0%; 63.7%)	22.3% (19.2%; 25.9%)	14.0% (11.4%; 17.1%)	620	60.0% (56.1%; 64.0%)	17.2% (14.4%; 20.6%)	11.1% (8.8%; 14.0%)
		III	206	38.4% (32.2%; 45.9%)	6.4% (3.7%; 10.9%)	2.8% (1.2%; 6.5%)	243	38.6% (32.9%; 45.3%)	6.0% (3.7%; 10.0%)	2.2% (1.0%; 5.1%)
		IV	1,083	18.3% (16.1%; 20.8%)	1.9% (1.2%; 2.9%)	1.3% (0.8%; 2.3%)	897	19.6% (17.2%; 22.5%)	2.0% (1.3%; 3.2%)	0.8% (0.4%; 1.7%)
		X/NA	724	20.9% (18.1%; 24.2%)	4.9% (3.5%; 6.9%)	3.0% (1.9%; 4.7%)	645	23.4% (20.3%; 27.0%)	4.3% (2.9%; 6.2%)	2.8% (1.7%; 4.5%)
	2010-2014	All	3,165	34.3% (32.6%; 36.0%)	9.3% (8.3%; 10.5%)	6.0% (5.1%; 6.9%)	2,895	35.7% (34.0%; 37.5%)	10.6% (9.5%; 11.8%)	6.3% (5.4%; 7.3%)
		I	182	59.1% (52.0%; 67.1%)	28.8% (22.5%; 37.0%)	23.4% (17.3%; 31.7%)	193	62.0% (55.3%; 69.6%)	37.2% (30.7%; 45.2%)	29.5% (23.2%; 37.4%)
		II	801	60.4% (57.0%; 64.0%)	21.5% (18.7%; 24.7%)	13.1% (10.8%; 15.9%)	741	59.7% (56.1%; 63.4%)	23.5% (20.5%; 26.9%)	13.2% (10.8%; 16.1%)
		III	238	38.4% (32.6%; 45.2%)	5.5% (3.2%; 9.4%)	2.4% (1.1%; 5.5%)	241	41.8% (36.0%; 48.7%)	5.2% (3.0%; 8.9%)	2.6% (1.2%; 5.6%)
		IV	1,351	19.6% (17.6%; 21.9%)	2.2% (1.5%; 3.2%)	0.8% (0.4%; 1.5%)	1,160	21.0% (18.8%; 23.5%)	1.8% (1.2%; 2.8%)	0.6% (0.3%; 1.2%)
		X/NA	593	23.0% (19.8%; 26.8%)	4.8% (3.3%; 7.1%)	4.0% (2.6%; 6.1%)	560	22.5% (19.2%; 26.3%)	4.6% (3.1%; 6.9%)	2.6% (1.5%; 4.5%)
	2015-2019	All	3,724	39.1% (37.6%; 40.8%)	13.5% (12.4%; 14.7%)	7.8% (6.9%; 8.8%)	3,472	41.1% (39.5%; 42.8%)	13.1% (12.0%; 14.4%)	8.4% (7.5%; 9.5%)
		I	279	69.9% (64.4%; 75.9%)	44.2% (38.2%; 51.1%)	32.5% (26.8%; 39.6%)	318	70.4% (65.4%; 75.9%)	43.4% (37.9%; 49.7%)	34.9% (29.6%; 41.3%)
		II	783	67.0% (63.6%; 70.5%)	28.7% (25.5%; 32.3%)	17.3% (14.6%; 20.4%)	732	63.0% (59.5%; 66.8%)	26.5% (23.3%; 30.0%)	18.3% (15.5%; 21.6%)
		III	429	57.4% (52.8%; 62.4%)	16.3% (13.0%; 20.4%)	7.8% (5.5%; 11.1%)	398	56.9% (52.1%; 62.1%)	14.0% (10.9%; 17.9%)	6.2% (4.1%; 9.2%)
		IV	1,847	20.9% (19.1%; 22.9%)	3.1% (2.4%; 4.0%)	1.0% (0.6%; 1.6%)	1,643	24.6% (22.6%; 26.8%)	3.1% (2.4%; 4.1%)	0.9% (0.5%; 1.5%)
		X/NA	386	27.1% (22.9%; 32.0%)	6.8% (4.6%; 10.0%)	3.3% (1.8%; 6.0%)	381	29.4% (25.0%; 34.5%)	4.5% (2.8%; 7.2%)	2.2% (1.0%; 4.6%)
	2020-2024	All	4,246	44.0% (42.5%; 45.6%)	15.2% (14.0%; 16.5%)	9.4% (8.2%; 10.8%)	4,115	43.6% (42.1%; 45.2%)	15.3% (14.1%; 16.5%)	9.1% (8.0%; 10.4%)
		I	512	67.8% (63.6%; 72.3%)	41.4% (36.7%; 46.7%)	29.3% (23.6%; 36.4%)	587	69.4% (65.6%; 73.4%)	41.0% (36.7%; 45.8%)	32.8% (28.1%; 38.4%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	668	64.4% (60.7%; 68.3%)	28.0% (24.3%; 32.3%)	19.3% (15.5%; 24.1%)	637	63.5% (59.7%; 67.5%)	27.7% (24.0%; 31.9%)	16.0% (12.3%; 20.7%)
		III	681	65.3% (61.7%; 69.1%)	21.4% (18.2%; 25.2%)	10.6% (7.7%; 14.7%)	670	58.0% (54.3%; 62.0%)	18.2% (15.3%; 21.8%)	8.6% (5.9%; 12.5%)
		IV	2,266	27.1% (25.3%; 29.1%)	3.9% (3.1%; 5.0%)	1.7% (1.0%; 2.7%)	2,108	26.9% (25.1%; 28.9%)	3.9% (3.0%; 4.9%)	0.6% (0.3%; 1.5%)
		X/NA	119	26.9% (19.8%; 36.5%)	9.7% (5.4%; 17.6%)	6.3% (2.8%; 14.5%)	113	22.7% (16.1%; 32.0%)	9.7% (5.4%; 17.3%)	6.1% (2.8%; 13.2%)
NENs	**2004-2009**	All	225	88.5% (84.0%; 93.2%)	79.9% (74.0%; 86.2%)	72.7% (65.8%; 80.4%)	210	87.6% (83.0%; 92.4%)	77.1% (71.1%; 83.5%)	72.6% (66.1%; 79.8%)
		I	38	N<50	N<50	N<50	42	N<50	N<50	N<50
		II	25	N<50	N<50	N<50	19	N<50	N<50	N<50
		III	5	N<50	N<50	N<50	2	N<50	N<50	N<50
		IV	62	73.7% (63.2%; 85.9%)	55.1% (43.5%; 69.9%)	33.8% (23.2%; 49.3%)	56	68.8% (57.5%; 82.3%)	41.7% (30.4%; 57.2%)	32.4% (21.7%; 48.3%)
		X/NA	95	93.7% (88.1%; 99.7%)	88.4% (80.3%; 97.3%)	86.6% (76.9%; 97.4%)	91	94.2% (89.2%; 99.5%)	90.8% (84.0%; 98.2%)	86.6% (78.0%; 96.0%)
	2010-2014	All	337	83.5% (79.3%; 87.8%)	70.4% (65.1%; 76.1%)	64.4% (58.6%; 70.8%)	292	87.3% (83.3%; 91.4%)	76.4% (71.3%; 81.8%)	69.7% (64.0%; 75.8%)
		I	102	95.1% (90.6%; 99.9%)	90.9% (83.6%; 98.7%)	90.4% (81.6%; 100.1%)	106	98.5% (95.8%; 101.2%)	93.6% (88.2%; 99.4%)	94.2% (88.4%; 100.4%)
		II	57	93.1% (86.0%; 100.8%)	86.3% (76.1%; 97.9%)	83.3% (71.6%; 97.1%)	38	N<50	N<50	N<50
		III	5	N<50	N<50	N<50	5	N<50	N<50	N<50
		IV	109	62.8% (54.1%; 72.8%)	39.7% (31.2%; 50.5%)	23.9% (16.7%; 34.2%)	84	72.5% (63.4%; 82.9%)	51.4% (41.3%; 63.9%)	31.7% (22.5%; 44.6%)
		X/NA	64	87.5% (79.3%; 96.6%)	75.7% (64.3%; 89.1%)	72.9% (60.5%; 87.7%)	59	89.4% (81.5%; 98.1%)	78.2% (67.7%; 90.2%)	79.5% (68.3%; 92.5%)
	2015-2019	All	474	83.3% (79.8%; 87.0%)	72.7% (68.2%; 77.4%)	70.8% (65.8%; 76.1%)	398	88.8% (85.6%; 92.2%)	80.6% (76.3%; 85.1%)	74.8% (69.8%; 80.0%)
		I	156	94.4% (90.2%; 98.8%)	93.1% (87.7%; 98.8%)	94.1% (87.2%; 101.6%)	148	97.6% (94.7%; 100.6%)	94.1% (89.3%; 99.2%)	94.0% (88.2%; 100.3%)
		II	72	92.1% (85.4%; 99.3%)	86.8% (77.9%; 96.7%)	86.7% (75.7%; 99.2%)	62	92.9% (86.3%; 100.0%)	81.4% (71.5%; 92.7%)	72.8% (61.2%; 86.5%)
		III	38	N<50	N<50	N<50	19	N<50	N<50	N<50
		IV	138	63.4% (55.7%; 72.3%)	36.2% (28.8%; 45.6%)	30.4% (23.2%; 39.7%)	101	67.1% (58.4%; 77.1%)	48.5% (39.4%; 59.7%)	35.1% (26.5%; 46.4%)
		X/NA	70	80.8% (71.5%; 91.2%)	71.8% (60.7%; 85.1%)	67.7% (54.9%; 83.6%)	68	95.2% (89.7%; 100.9%)	91.8% (83.5%; 100.9%)	86.2% (75.2%; 98.9%)
	2020-2024	All	747	86.7% (84.1%; 89.4%)	77.8% (74.1%; 81.7%)	74.3% (69.4%; 79.5%)	543	88.2% (85.3%; 91.1%)	81.2% (77.3%; 85.2%)	79.2% (74.2%; 84.5%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	302	98.1% (95.9%; 100.5%)	98.8% (95.4%; 102.3%)	100.0% (94.2%; 106.1%)	260	96.6% (94.1%; 99.3%)	94.0% (89.9%; 98.3%)	94.1% (88.4%; 100.2%)
		II	132	95.0% (90.7%; 99.5%)	85.6% (77.2%; 95.0%)	80.2% (69.8%; 92.2%)	89	93.7% (88.7%; 99.1%)	92.8% (85.5%; 100.7%)	91.8% (82.6%; 102.0%)
		III	82	89.6% (82.7%; 97.0%)	83.2% (73.8%; 93.8%)	72.9% (58.1%; 91.5%)	37	N<50	N<50	N<50
		IV	203	63.3% (56.8%; 70.5%)	39.1% (31.9%; 47.9%)	32.7% (24.4%; 43.9%)	122	65.7% (57.7%; 74.8%)	43.6% (34.9%; 54.5%)	35.3% (25.4%; 49.0%)
		X/NA	28	N<50	N<50	N<50	35	N<50	N<50	N<50
Other and unspecified	**2004-2009**	All	571	17.7% (14.7%; 21.2%)	3.9% (2.5%; 6.0%)	1.9% (1.0%; 3.7%)	606	14.4% (11.7%; 17.6%)	4.0% (2.6%; 6.1%)	2.1% (1.1%; 4.0%)
		I	32	N<50	N<50	N<50	39	N<50	N<50	N<50
		II	55	28.8% (18.8%; 44.2%)	11.9% (5.6%; 25.1%)	6.7% (2.4%; 18.3%)	73	21.7% (14.0%; 33.6%)	6.5% (2.7%; 15.7%)	4.8% (1.4%; 16.3%)
		III	46	N<50	N<50	N<50	47	N<50	N<50	N<50
		IV	228	7.8% (4.9%; 12.2%)	FU<3y	FU<3y	213	9.8% (6.5%; 14.7%)	1.2% (0.4%; 4.1%)	0.6% (0.1%; 2.9%)
		X/NA	210	22.6% (17.5%; 29.3%)	5.9% (3.3%; 10.4%)	3.4% (1.5%; 7.6%)	234	13.7% (9.8%; 19.2%)	4.7% (2.5%; 8.8%)	1.9% (0.7%; 5.4%)
	2010-2014	All	590	20.1% (17.0%; 23.8%)	8.6% (6.4%; 11.4%)	7.4% (5.3%; 10.3%)	701	21.1% (18.2%; 24.4%)	8.2% (6.2%; 10.7%)	7.0% (5.1%; 9.6%)
		I	61	56.7% (44.9%; 71.7%)	38.3% (26.8%; 54.8%)	34.1% (22.3%; 52.1%)	77	38.7% (28.8%; 51.9%)	21.8% (13.6%; 35.0%)	20.8% (12.4%; 35.0%)
		II	63	21.4% (13.2%; 34.7%)	7.4% (3.0%; 17.9%)	7.4% (3.0%; 17.9%)	66	32.4% (22.5%; 46.8%)	9.5% (4.3%; 21.2%)	9.5% (4.3%; 21.2%)
		III	62	18.3% (10.8%; 31.0%)	1.8% (0.4%; 8.4%)	1.8% (0.4%; 8.4%)	67	39.8% (29.5%; 53.5%)	8.0% (3.6%; 17.9%)	5.1% (1.8%; 14.4%)
		IV	247	11.1% (7.8%; 15.9%)	2.4% (1.1%; 5.6%)	0.4% (0.1%; 2.4%)	274	10.1% (7.1%; 14.4%)	2.8% (1.4%; 5.6%)	2.5% (1.2%; 5.2%)
		X/NA	157	20.2% (14.7%; 27.8%)	9.7% (5.8%; 16.1%)	9.4% (5.5%; 15.9%)	217	19.4% (14.7%; 25.7%)	9.8% (6.2%; 15.3%)	6.9% (3.9%; 12.2%)
	2015-2019	All	669	21.8% (18.8%; 25.4%)	12.4% (9.9%; 15.5%)	9.4% (6.9%; 12.8%)	808	16.3% (13.9%; 19.2%)	7.7% (5.9%; 10.0%)	5.5% (3.9%; 7.8%)
		I	87	55.8% (45.7%; 68.3%)	41.1% (30.7%; 55.0%)	36.1% (25.0%; 52.3%)	100	32.7% (24.4%; 43.8%)	21.4% (14.2%; 32.2%)	18.9% (11.4%; 31.2%)
		II	73	34.0% (24.4%; 47.4%)	18.1% (10.5%; 31.1%)	7.9% (2.9%; 21.5%)	85	29.9% (21.4%; 41.8%)	10.8% (5.7%; 20.3%)	8.9% (4.2%; 18.7%)
		III	69	10.4% (5.2%; 21.0%)	3.1% (0.9%; 10.5%)	1.7% (0.4%; 8.2%)	60	24.7% (15.8%; 38.6%)	9.1% (4.0%; 20.8%)	2.3% (0.4%; 13.0%)
		IV	300	8.0% (5.4%; 11.8%)	0.7% (0.2%; 2.6%)	0.7% (0.2%; 2.6%)	391	5.7% (3.8%; 8.5%)	1.1% (0.4%; 2.8%)	0.3% (0.1%; 1.4%)
		X/NA	140	29.4% (22.6%; 38.4%)	20.5% (14.2%; 29.5%)	15.9% (9.4%; 26.8%)	172	21.5% (16.0%; 28.9%)	11.7% (7.5%; 18.2%)	8.3% (4.6%; 15.0%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	2020-2024	All	742	23.3% (20.4%; 26.7%)	12.2% (9.7%; 15.3%)	10.6% (7.4%; 15.0%)	841	21.9% (19.2%; 25.0%)	11.8% (9.6%; 14.6%)	10.4% (7.3%; 14.8%)
		I	129	53.2% (44.7%; 63.3%)	38.1% (29.2%; 49.8%)	32.7% (20.7%; 51.6%)	165	47.9% (40.4%; 56.7%)	34.1% (26.5%; 43.9%)	37.1% (28.1%; 49.1%)
		II	71	32.1% (22.7%; 45.4%)	15.0% (8.2%; 27.6%)	8.8% (3.4%; 22.8%)	103	31.0% (23.0%; 41.7%)	16.7% (9.9%; 28.0%)	FU<5y
		III	93	29.8% (21.5%; 41.2%)	13.6% (7.7%; 24.2%)	8.0% (2.8%; 22.9%)	114	18.2% (12.2%; 27.1%)	2.8% (1.0%; 8.4%)	FU<5y
		IV	400	7.2% (5.0%; 10.3%)	0.7% (0.2%; 2.4%)	FU<5y	398	6.4% (4.4%; 9.4%)	FU<3y	FU<3y
		X/NA	49	N<50	N<50	N<50	61	44.0% (32.7%; 59.3%)	34.4% (22.8%; 51.7%)	26.0% (13.5%; 50.3%)

6.1. Pancreatic cancer mortality: by region

6.1.1. Pancreatic cancer mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Males																						
Belgium	0	0	0	0	0	0	2	2	10	15	22	59	110	130	185	170	149	96	52	1	1,003	18.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[2.6]	[4.0]	[5.6]	[14.7]	[29.4]	[40.9]	[69.5]	[83.6]	[119.3]	[120.4]	[166.0]	[16.5]	[17.4]	(17.7; 20.0)
Brussels	0	0	0	0	0	0	0	0	1	1	3	5	6	8	10	7	9	6	3	0	59	15.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[2.3]	[7.3]	[14.1]	[20.8]	[37.5]	[59.4]	[55.4]	[111.9]	[119.9]	[130.3]	[0.0]	[9.7]	(11.7; 20.0)
Flanders	0	0	0	0	0	0	2	2	4	9	9	35	58	86	105	100	91	73	27	0	601	17.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[1.8]	[4.3]	[3.9]	[14.4]	[25.3]	[43.9]	[64.0]	[76.7]	[110.4]	[135.7]	[129.8]	[0.0]	[17.9]	(16.4; 19.2)
Wallonia	0	0	0	0	0	0	0	0	5	5	10	19	46	36	70	63	49	17	22	1	343	21.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.3]	[4.2]	[8.0]	[15.2]	[39.3]	[35.7]	[82.0]	[104.5]	[142.5]	[81.2]	[267.4]	[64.4]	[19.0]	(19.4; 24.1)
Females																						
Belgium	0	0	0	0	0	0	1	1	4	10	27	45	95	117	140	184	143	136	65	19	987	14.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[1.0]	[2.7]	[7.0]	[11.3]	[24.9]	[34.6]	[47.1]	[74.9]	[82.1]	[101.6]	[91.7]	[91.3]	[16.6]	(13.8; 15.7)
Brussels	0	0	0	0	0	0	0	0	0	2	1	4	8	9	14	15	14	8	6	3	84	16.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.9]	[2.6]	[11.7]	[26.5]	[36.0]	[65.3]	[83.3]	[109.0]	[81.6]	[105.8]	[144.1]	[13.3]	(12.9; 20.1)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	1	0	3	4	17	20	61	64	79	125	86	90	33	9	592	14.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[1.4]	[1.9]	[7.6]	[8.5]	[26.7]	[31.7]	[45.0]	[83.2]	[78.6]	[105.5]	[75.0]	[73.5]	[17.3]	(13.4; 15.7)
Wallonia	0	0	0	0	0	0	0	1	1	4	9	21	26	44	47	44	43	38	26	7	311	14.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.8]	[3.4]	[7.2]	[16.6]	[21.1]	[39.5]	[47.0]	[56.8]	[82.8]	[98.3]	[122.7]	[108.0]	[16.5]	(13.1; 16.4)

7.1. Pancreatic cancer mortality trends: by region

7.1.1. Pancreatic cancer mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	671	720	678	728	769	706	796	795	789	823	787	815	853	900	948	843	893	900	1,003	1,003		
	CR	13.2	14.1	13.2	14.1	14.7	13.4	15.0	14.8	14.6	15.1	14.4	14.8	15.4	16.2	16.9	15.0	15.8	15.9	17.6	17.4		
	ESR2013	18.0	18.6	17.6	18.3	19.1	17.2	18.3	18.6	17.8	18.3	17.1	17.4	18.1	18.9	19.4	17.0	17.5	17.7	19.2	18.9	0.0 (-0.3; 0.4)	2004-2023
Brussels	**N**	55	57	57	67	79	59	61	63	68	61	57	69	73	65	67	61	63	73	67	59		
	CR	11.5	11.8	11.6	13.5	15.6	11.4	11.6	11.6	12.3	10.9	10.1	12.0	12.6	11.2	11.4	10.3	10.5	12.2	11.2	9.7		
	ESR2013	17.5	17.6	17.9	21.5	26.0	19.0	17.8	18.6	21.0	17.6	16.3	19.6	20.6	18.5	17.8	16.9	17.0	19.9	18.4	15.9	-0.6 (-1.4; 0.3)	2004-2023
Flanders	**N**	370	420	402	406	451	422	468	461	453	491	446	477	486	535	584	540	546	504	589	601		
	CR	12.5	14.1	13.4	13.5	14.8	13.8	15.2	14.8	14.4	15.6	14.1	15.0	15.2	16.6	18.0	16.6	16.6	15.3	17.8	17.9		
	ESR2013	16.4	17.6	17.2	16.5	18.1	16.3	17.6	17.3	16.2	17.6	15.7	16.3	16.5	18.0	19.3	17.3	17.2	15.8	17.9	17.8	0.2 (-0.3; 0.6)	2004-2023
Wallonia	**N**	246	243	219	255	239	225	267	271	268	271	284	269	294	300	297	242	284	323	347	343		
	CR	15.0	14.7	13.2	15.3	14.2	13.3	15.7	15.8	15.5	15.6	16.3	15.4	16.7	17.0	16.8	13.6	15.9	18.1	19.4	19.0		
	ESR2013	21.5	21.0	18.5	21.1	19.0	18.6	20.0	21.2	20.2	20.1	20.1	19.2	20.5	20.9	19.9	16.2	18.5	21.0	21.9	21.8	0.0 (-0.6; 0.6)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Pancreatic cancer mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	628	724	732	731	741	732	806	854	799	840	859	895	852	947	904	946	961	1,005	1,010	987		
	CR	11.8	13.6	13.6	13.5	13.6	13.3	14.6	15.3	14.2	14.9	15.1	15.7	14.9	16.5	15.6	16.3	16.5	17.2	17.2	16.6		
	ESR2013	11.7	13.4	13.3	13.2	13.0	12.7	14.0	14.4	13.3	13.9	14.1	14.4	13.7	15.0	14.2	14.7	14.6	15.2	15.1	14.8	1.0 (0.7; 1.2)	2004-2023
Brussels	**N**	61	76	79	64	60	94	69	65	85	81	71	75	70	77	75	88	55	72	79	84		
	CR	11.7	14.5	14.9	12.0	11.1	17.0	12.3	11.3	14.5	13.7	11.9	12.4	11.5	12.6	12.3	14.3	8.9	11.6	12.7	13.3		
	ESR2013	12.1	15.5	15.2	13.2	11.5	18.4	13.6	12.9	16.3	14.9	13.6	14.2	13.6	15.8	14.7	16.0	10.6	13.7	15.1	16.5	0.3 (-0.8; 1.4)	2004-2023
Flanders	**N**	346	403	413	403	431	426	468	473	456	462	485	497	506	538	533	556	591	595	598	592		
	CR	11.3	13.2	13.4	13.0	13.8	13.5	14.8	14.8	14.2	14.3	14.9	15.2	15.4	16.3	16.1	16.7	17.6	17.7	17.7	17.3		
	ESR2013	11.2	12.9	12.8	12.5	12.9	12.6	13.8	13.5	12.9	13.0	13.4	13.6	13.5	14.1	13.8	14.4	14.8	14.8	14.5	14.6	1.0 (0.8; 1.3)	2004-2023
Wallonia	**N**	221	245	240	264	250	212	269	316	258	297	303	323	276	332	296	302	315	338	333	311		
	CR	12.7	14.0	13.7	14.9	14.1	11.9	15.0	17.4	14.2	16.2	16.5	17.6	15.0	17.9	16.0	16.3	16.9	18.1	17.8	16.5		
	ESR2013	12.7	13.9	13.4	14.6	13.5	11.4	14.4	16.6	13.3	15.3	15.5	16.2	14.0	16.7	14.7	14.9	15.3	16.5	15.9	14.7	1.0 (0.3; 1.6)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026